CELLINK and Nanyang Technological University have signed a collaboration agreement where the University’s Singapore Centre for 3D Printing (SC3DP) and CELLINK will jointly open a Research, Innovation and Development lab to investigate key research areas with the intention to validate the impact of bioprinting. This joint lab will serve to increase exposure of the technology within Singapore.
CELLINK has entered a collaboration agreement with Nanyang Technological University (NTU), a leading institute in Singapore, to jointly investigate key 3D bioprinting applications to further advance the contributions of 3D bioprinting on the future of healthcare. As part of the agreement, CELLINK will provide its industry leading knowledge to support researchers at NTU progress their bioprinting projects.
The collaboration agreement will explore topics like the development of effective blood brain models to understand how drug delivery and uptake functions in the body, advancement of bone tissue engineering and regeneration as well as bio fabricating vascularized skin for In vitro studies and eventually In vivo application.
In addition to advancing research in critical application areas, this project will also increase awareness of the capabilities of 3D bioprinting, enabling scientists at NTU to master advanced bioprinting technologies and further incorporate them in their research.
“We are thrilled to be working with such a prestigious institute like NTU and a world renowned professor like Prof. Bartolo. We are confident that this synergistic approach will help drive and validate multiple critical use cases of 3D bioprinting which may enable the future of life saving treatments globally.” – said Cecilia Edebo, CEO CELLINK.
“This is a major step in the lifetime of SC3DP, and we are delighted to have CELLINK as a partner. An expansion of the facility in to the biofabrication realm alongside CELLINK will enable a wider degree of research projects and will further establish the institute as a leader within the additive manufacturing field. We look forward to working along side CELLINK and their scientists to uncover discoveries that can rapidly accelerate translational technologies and contribute to an improving healthcare landscape” – said Prof. Paulo Jorge Da Silva Bartolo, Executive Director SC3DP.
For further information, please contact:
Avijit Minocha, Head of Marketing, CELLINK
Phone: +1 617 637 5372
CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.